No profile data available.
Gyre Therapeutics, Inc. (GYRE) is a healthcare company in the lung treatment pharmaceuticals industry, based in San Diego, United States, with about 625 full-time employees.
It reported revenue of $116.59 million for fiscal year 2025, up 10.2% from fiscal year 2024, and net income of $5.03 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $29.11 million, up 8.7% from a year before. Its market capitalization was $746.48 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Gyre Therapeutics reported $116.59 million in revenue for fiscal year 2025, up 10.2% from $105.76 million in fiscal year 2024. In Q2 2026 revenue was $29.11 million.
$746.48 million as of October 9, 2026.
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include Innoviva, Inc. (INVA), Upstream Bio, Inc. (UPB), Savara Inc. (SVRA), 4D Molecular Therapeutics, Inc. (FDMT).